Transcription of AACE COMPREHENSIVE TYPE 2 DIABETES 2 0
{{id}} {{{paragraph}}}
Example: stock market
AACE COMPREHENSIVE TYPE 2 DIABETES 2 0
COPYRIGHT 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. | DOI ASSOCIATION OF CLINICAL ENDOCRINOLOGYAACE COMPREHENSIVETYPE 2 DIABETESMANAGEMENT ALGORITHMCOPYRIGHT 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. | DOI 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. | DOI for Treatment of Type 2 Model for Care of the Patient with Risk Factor of Antihyperglycemic MedicationsTABLE OF CONTENTSCOMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHMCOPYRIGHT 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. | DOI OF THE AACE/ACE COMPREHENSIVETYPE 2 DIABETES MANAGEMENT modification underlies all therapy ( , weight control, physical activity, sleep, etc.) weight all glycemic targets (A1C, FPG, PPG) A1C is , or as close to normal as is safe and choices are patient centric based on A1C at presentation and shared of therapy reflects ASCVD, CHF, and renal must be managed for COMPREHENSIVE to goal as soon as possible adjust at 3 months until at of therapy includes ease of use and is highly recommended, as available, to assist patients in reaching goals safelyCOPYRIGHT 2020 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE.
lifestyle therapy and ongoing glucose monitoring cgm preferred independent of glycemic control if established or high ascvd risk and/or ckd recommend sglt2i and/or la glp1-ra progression of disease glycemic control algorithm met or other agent dual therapy1 glp1-ra sglt2i dpp4i td su/gln basal insulin colesevelam bromocriptine r agi no yes ...
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: